Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results

Fig. 2

ALSFRS-R slopes analysis in run-in, and 3-, 6- and 12-month follow up after AstroRx® treatment. The change in slopes between pre-treatment slope ("Run-in") and post-treatment slope over 12 months was analyzed by using a repeated mixed model with fit least squares (LS) means (MMRM analysis). Analysis was performed on Cohort A, Cohort B, Cohort A&B as well as on rapid progressors (defined by ALSFRS-R≤1.1/month during run-in). * = P value=0.039 (Run-in vs. 3-month FU, & = P value=0.002 (Run-in vs. 3-month FU) and # = P value <0.001 (Run-in vs. 3-month FU)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us